查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465067

性行為感染傳染病診斷市場：按疾病類型、診斷方法、設備類型和最終用戶分類 - 全球預測 2024-2030

Sexually Transmitted Disease Diagnostics Market by Disease Type, Diagnostic methods, Device Type, End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年性行為感染傳染病診斷市場規模為1,065.3億美元，預估2024年將達1,125.6億美元，2030年將達1,599.7億美元，複合年成長率為5.97%。

性行為感染傳染病診斷是指用於識別透過性接觸傳播的感染疾病的一系列醫學測試、身體檢查和程序。這些診斷對於性行為感染的早期發現、治療和預防、支持公共衛生工作和個人福祉至關重要。診斷性行為感染傳染病 (STD) 的方法有很多種，包括基於實驗室的測試，例如核酸增幅檢查、培養和酵素免疫分析法(EIA)，以及提供就地檢驗。全球性傳染病盛行率的上升極大地促進了診斷劑的成長。這一成長是由於性行為的變化、缺乏性健康教育和意識以及某些地區的篩檢計劃不足所造成的。這強調了對有效診斷解決方案的需求，並推動了對性病診斷的需求不斷成長。然而，與性病相關的社會恥辱仍然是性病診斷提供者面臨的主要挑戰。上市公司越來越關注性病預防和控制，將其作為公共衛生的一部分。此外，分子診斷、聚合酵素鏈鎖反應（PCR）檢測和免疫檢測等醫學診斷技術的快速發展顯著提高了性病檢測的準確性、效率和速度。這些技術進步有利於性病的早期發現和治療，進一步促進性病診斷的成長。

主要市場統計
基準年[2023] 1065.3億美元
預測年份 [2024] 1125.6億美元
預測年份 [2030] 1599.7億美元
複合年成長率（%） 5.97%

疾病類型次世代定序儀和基於 CRISPR 的診斷方法的進步使得治療多種性傳染病成為可能。

性行為感染傳染病 (STD) 診斷研究包括影響性健康的多種疾病。其中包括細菌性陰道炎，這是由陰道細菌失衡引起的，會導致陰道分泌物和不適等症狀。念珠菌性陰道炎或酵母菌感染疾病是由念珠菌過度生長引起的，會引起搔癢和發炎。另一方面，透過性接觸傳播的感染疾病，例如披衣菌感染衣原體和淋病奈瑟菌，通常不會立即引起症狀，如果不及時治療，可能會導致嚴重的生殖問題。生殖器濕疣是由某些 HPV 菌株引起的，在生殖器部位表現為疣。愛滋病毒/愛滋病嚴重削弱免疫系統，導致危及生命的感染疾病。一種鮮為人知的細菌，稱為生殖黴漿菌，與尿道炎和發炎等疾病有關。梅毒是一種分階段進展的細菌感染疾病，最初會引起潰瘍和皮疹，如果不治療，會導致內臟器官嚴重受損。最後，滴蟲性陰道炎是由滴蟲原生動物引起的，其特徵是搔癢和分泌物，但通常可以用抗生素治癒。

最終使用者：臨床和醫院環境中擴大採用性病診斷來解決複雜的性病病例。

性行為感染傳染病 (STD) 診斷有多種醫療保健和監測設置，每種設置在 STD 檢測、分析和管理中都發揮著重要作用。診所通常是性病診斷的前線，提供公眾可以直接獲得的檢測服務。診斷實驗室專門使用先進技術分析檢體以獲得準確的結果。醫院提供包括性病診斷在內的綜合治療，特別是需要住院治療的重症、複雜病例。公共衛生機構透過使用診斷資料為公共衛生策略和干涉措施提供訊息，對於監測、預防和控制性傳染病至關重要。此外，研究機構在開發新的診斷方法和了解性傳染病的流行病學方面發揮著重要作用，有助於建立推進公共衛生措施和臨床實踐所需的科學基礎設施。

區域洞察

美洲性行為感染(STD) 的盛行率不斷上升，加上健康意識和醫療保健支出的增加，正在推動對診斷解決方案的需求。先進的醫療保健基礎設施和尖端診斷技術的高普及有助於提高消費者的期望。最近的努力包括對公共衛生計劃進行大量投資，以加強弱勢群體的性病診斷。同時，歐洲、中東和非洲正在展示一種積極主動的性病診斷方法，並得到政府和非政府計劃的支持，促進創新診斷解決方案的研究、開發和分銷。注重性價比、全面覆蓋，實現都市區便捷使用。近年來，亞太地區在教育、意識和減少性傳染病恥辱方面的努力逐漸取得進展，導致對診斷服務的需求逐漸增加。此外，由於人們對性病的認知不斷提高、性病患病率不斷上升以及政府旨在控制這些感染疾病的舉措，亞太地區熱衷於發展性病診斷市場。由於中國、印度、日本和澳洲等國家的人口多樣化和醫療基礎設施多樣化，先進技術的採用和對具有成本效益的診斷解決方案不斷成長的需求推動了市場動態。

FPNV定位矩陣

FPNV 定位矩陣對於評估性行為感染傳染病診斷市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對性行為感染診斷市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.性行為感染傳染病診斷市場的市場規模和預測是多少？

2.在性行為感染診斷市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.性行為感染傳染病診斷市場的技術趨勢和法規結構是什麼？

4.性行為感染診斷市場主要廠商的市場佔有率為何？

5.進入性行為感染診斷市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球性傳染病的日益普及增加了對有效診斷解決方案的需求
      • 在全球範圍內增加檢測，以減少與性行為感染相關的恥辱
    • 抑制因素
      • 對性行為感染傳染病缺乏足夠的認知與教育
    • 機會
      • 增加對性行為感染傳染病的認知和預防的資金和公共衛生宣傳活動
      • 次世代定序和基於 CRISPR 的診斷的創新
    • 任務
      • 關於藥物核准和未經治療的感染疾病引起的併發症的嚴格政府法規
  • 市場區隔分析
    • 疾病類型：次世代定序和基於 CRISPR 的診斷技術的進步可解決多種 STD
    • 最終用戶：在臨床和醫院環境中更多地採用性行為感染診斷來解決複雜的性行為感染病例
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章性行為感染傳染病診斷市場：依疾病類型

  • 細菌性陰道炎
  • 念珠菌性陰道炎
  • 披衣菌感染披衣菌/淋病雙球菌
  • 尖圭濕疣
  • B型肝炎
  • HIV愛滋病
  • 黴漿菌支原體
  • 梅毒
  • 滴蟲病

第7章依診斷方法性行為感染傳染病診斷藥物市場

  • 抗原檢測
  • 分子診斷
  • 血清學檢測

第8章按設備類型性行為感染傳染病診斷市場

  • 實驗裝置
  • 照護現場設備

第9章性行為感染傳染病診斷市場：依最終用戶分類

  • 診所
  • 診斷實驗室
  • 醫院
  • 公共衛生機構
  • 調查機構

第10章 南北美洲性行為感染診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太性行為感染診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東、非洲性行為感染診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 英國Start-Ups推出具有性行為感染感染測試功能的衛生棉條
    • BioPerfectus 推出新型 PCR套件，用於性行為感染傳染病診斷解決方案
    • MyLab 推出性行為感染傳染病快速檢測
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-6D54EA0F9447

[180 Pages Report] The Sexually Transmitted Disease Diagnostics Market size was estimated at USD 106.53 billion in 2023 and expected to reach USD 112.56 billion in 2024, at a CAGR 5.97% to reach USD 159.97 billion by 2030.

Sexually transmitted disease diagnostics refers to the range of medical tests, physical examinations, and procedures used to identify infections transmitted through sexual contact. These diagnostics are crucial for the early detection, treatment, and prevention of sexually transmitted diseases, supporting public health efforts and individual well-being. The methodologies for Sexually transmitted disease (STD) diagnostics vary, including laboratory-based tests such as nucleic acid amplification tests, cultures, enzyme immunoassays (EIAs), and point-of-care tests that offer rapid results. The rising prevalence of STDs worldwide is a major contributor to the growth of diagnostics. This increase is attributed to changing sexual behaviors, lack of education and awareness regarding sexual health, and insufficient screening programs in certain regions. The need for effective diagnostic solutions is thus highlighted, prompting an uptick in demand for STD diagnostics. However, the social stigma associated with STDs remains a significant challenge for STD diagnostic providers. Companies are increasingly focusing on STD prevention and control as part of their public health initiatives. Moreover, the rapid progress in medical diagnostic technologies, including molecular diagnostics, Polymerase Chain Reaction (PCR) testing, and immunoassays, has significantly enhanced the accuracy, efficiency, and speed of STD testing. These technological advancements facilitate the early detection and treatment of STDs, further driving the growth of STD diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 106.53 billion
Estimated Year [2024] USD 112.56 billion
Forecast Year [2030] USD 159.97 billion
CAGR (%) 5.97%

Disease Type: Advancements in next-generation sequencing and CRISPR-based diagnostics to cater varied STDs

The study of sexually transmitted disease (STD) diagnostics encompasses a broad range of conditions affecting sexual health. These include bacterial vaginosis, a condition stemming from an imbalance of bacteria in the vagina, which leads to symptoms such as discharge and discomfort. Candidal vaginitis or yeast infection arises from an overgrowth of Candida fungi, causing itching and irritation. On the other hand, infections such as Chlamydia trachomatis and Neisseria Gonorrhoeae, transmitted through sexual contact, often show no immediate symptoms and can lead to severe reproductive issues that are left unaddressed. Genital Warts are the result of certain HPV strains, presenting as warts on the genital area. HIV/AIDS severely impairs the immune system, leading to life-threatening infections. The bacterium Mycoplasma genitalium, though lesser known, is linked to conditions such as urethritis and pelvic inflammatory disease. Syphilis, a bacterial infection, progresses through stages, initially causing sores and skin rashes and, without treatment, severe damage to internal organs. Lastly, Trichomoniasis, caused by the Trichomonas vaginalis protozoan, is characterized by itching and discharge but is typically curable with antibiotics.

End-Users: Increasing adoption of STD diagnostics in clinical and hospital settings to cater complicated STD cases

Sexually transmitted disease (STD) diagnostics encompass various healthcare and research settings, each playing an important role in the detection, analysis, and management of STDs. Clinics are often the frontline in STD diagnostics, providing accessible testing services directly to the public. Diagnostic laboratories specialize in the analysis of samples, utilizing advanced technologies to ensure accurate results. Hospitals offer comprehensive care, including STD diagnostics, especially in more severe or complicated cases that require in-patient care. Public health agencies are integral to the surveillance, prevention, and control of STDs, using diagnostic data to inform public health strategies and interventions. Moreover, research institutions are key in developing new diagnostic methods and understanding the epidemiology of STDs, contributing to the scientific foundation necessary for advancing public health measures and clinical practices.

Regional Insights

In the Americas, the growing prevalence of sexually transmitted diseases (STDs), coupled with increased health awareness and healthcare spending, propels demand for diagnostic solutions. Advanced healthcare infrastructure and the high adoption of cutting-edge diagnostic technologies contribute to sophisticated consumer expectations. Recent initiatives include significant investments in public health programs to enhance STD diagnostics among underprivileged populations. At the same time, the EMEA shows a proactive approach towards STD diagnostics, supported by governmental and non-governmental initiatives that facilitate research, development, and distribution of innovative diagnostics solutions. The emphasis is on cost-effectiveness and comprehensive coverage, aiming for urban and rural accessibility. In recent years, the region has witnessed gradual progress with initiatives aimed at education, awareness, and breaking the stigma around STDs, slowly increasing the demand for diagnostic services. Moreover, the Asia-Pacific region is keen on growth in the market for STD diagnostics, driven by increasing awareness, rising prevalence of STDs, and government initiatives aimed at curbing these infections. With a diverse population and varying healthcare infrastructure across countries, including China, India, Japan, and Australia, the market dynamics are characterized by a mix of advanced technological adoption and growing demand for cost-effective diagnostic solutions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Sexually Transmitted Disease Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Sexually Transmitted Disease Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Sexually Transmitted Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astra Biotech Gmbh, Becton Dickinson and company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd, Geneproof, Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., MedMira Inc, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., OraSure Technologies, Inc., Qiagen Inc, Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Sexually Transmitted Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Bacterial Vaginosis
    • Candidal Vaginitis
    • Chlamydia Trachomatis/ Neisseria Gonorrhoeae
    • Genital Warts
    • Hepatitis B
    • HIV/AIDS
    • Mycoplasma Genitalium
    • Syphilis
    • Trichomoniasis
  • Diagnostic methods
    • Antigen Detection
    • Molecular Diagnostics
    • Serologic Testing
  • Device Type
    • Laboratory Devices
      • Absorbance Microplate Reader
      • Differential Light Scattering Machines
      • Flow Cytometers
      • Lateral Flow Readers
      • Thermal Cyclers - PCR
    • Point of Care Devices
      • Phone Chips (Microfluidics + ICT)
      • Rapid Diagnostic Kits
  • End-Users
    • Clinics
    • Diagnostic Laboratories
    • Hospitals
    • Public Health Agencies
    • Research Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Sexually Transmitted Disease Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Sexually Transmitted Disease Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Sexually Transmitted Disease Diagnostics Market?

4. What is the market share of the leading vendors in the Sexually Transmitted Disease Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Sexually Transmitted Disease Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. The rising prevalence of sexual diseases worldwide and the need for effective diagnostic solutions
      • 5.1.1.2. Increasing implementation of worldwide screening to reduce the stigma associated with STD
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of adequate awareness and education about STDs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased funding and public health campaigns for STD awareness and prevention
      • 5.1.3.2. Innovations in next-generation sequencing and CRISPR-based diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations for drug approvals and complications arising from untreated infections
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Advancements in next-generation sequencing and CRISPR-based diagnostics to cater varied STDs
    • 5.2.2. End-Users: Increasing adoption of STD diagnostics in clinical and hospital settings to cater complicated STD cases
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Sexually Transmitted Disease Diagnostics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Bacterial Vaginosis
  • 6.3. Candidal Vaginitis
  • 6.4. Chlamydia Trachomatis/ Neisseria Gonorrhoeae
  • 6.5. Genital Warts
  • 6.6. Hepatitis B
  • 6.7. HIV/AIDS
  • 6.8. Mycoplasma Genitalium
  • 6.9. Syphilis
  • 6.10. Trichomoniasis

7. Sexually Transmitted Disease Diagnostics Market, by Diagnostic methods

  • 7.1. Introduction
  • 7.2. Antigen Detection
  • 7.3. Molecular Diagnostics
  • 7.4. Serologic Testing

8. Sexually Transmitted Disease Diagnostics Market, by Device Type

  • 8.1. Introduction
  • 8.2. Laboratory Devices
  • 8.3. Point of Care Devices

9. Sexually Transmitted Disease Diagnostics Market, by End-Users

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals
  • 9.5. Public Health Agencies
  • 9.6. Research Institutions

10. Americas Sexually Transmitted Disease Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Sexually Transmitted Disease Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Sexually Transmitted Disease Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. British startup launches tampon that offers STI screening
    • 13.3.2. BioPerfectus Launches New PCR Kits for Sexually Transmitted Diseases Diagnostic Solution
    • 13.3.3. Mylab Launches rapid tests for sexually transmitted diseases
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL VAGINOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL VAGINOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDAL VAGINITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDAL VAGINITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS/ NEISSERIA GONORRHOEAE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS/ NEISSERIA GONORRHOEAE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MYCOPLASMA GENITALIUM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MYCOPLASMA GENITALIUM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SEROLOGIC TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SEROLOGIC TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ABSORBANCE MICROPLATE READER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ABSORBANCE MICROPLATE READER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIFFERENTIAL LIGHT SCATTERING MACHINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIFFERENTIAL LIGHT SCATTERING MACHINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW READERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW READERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY THERMAL CYCLERS - PCR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY THERMAL CYCLERS - PCR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PHONE CHIPS (MICROFLUIDICS + ICT), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PHONE CHIPS (MICROFLUIDICS + ICT), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC KITS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC KITS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 81. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 82. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 83. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 84. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 95. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 96. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 105. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 106. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 107. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 108. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 117. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 118. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 119. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 120. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 129. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 130. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 131. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 132. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 143. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 144. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 145. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 146. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 168. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 170. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 172. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 180. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 181. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 182. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 183. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 184. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 192. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 193. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 194. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 195. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 196. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 204. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 205. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 206. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 207. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 208. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 216. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 217. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 218. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 219. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 220. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 228. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 229. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 230. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 231. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 232. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 240. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 241. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 242. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 243. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 244. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 252. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 253. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 254. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 255. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 256. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 264. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 265. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 266. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 267. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 268. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. TAIWAN SEXUALLY